Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

Since the discovery of echinoderm microtubule-associated protein-like 4 (EML4) and
anaplastic lymphoma kinase (ALK) gene fusion in non-small cell lung carcinoma (NSCLC) …

Lung cancer is one of the most common malignant neoplasms. As a result of the disease's
progression, patients may develop metastases to the central nervous system. The prognosis …

Cancer is one of the leading causes of death worldwide and remains a major public health
challenge. The introduction of more sensitive and powerful technologies has permitted the …

Targeted kinase inhibitors improve the prognosis of lung cancer patients with ALK
alterations (ALK+). However, due to the emergence of acquired resistance and varied …

Introduction This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and
safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib …

Background Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung
cancer (ALK+ NSCLC), but clinical courses vary widely. Early identification and molecular …

Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …